ATARA Biotherapeutics (NASDAQ: ATRA) reported Q2 EPS of ($0.32), $0.10 worse than the analyst estimate of ($0.22). Revenue for the quarter came in at $630 thousand versus the consensus estimate of $2.55 million.

For earnings history and earnings-related data on ATARA Biotherapeutics (ATRA) click here.